Combination therapy with PCSK9 mAbs in post-MI patients10' education - Sep. 22, 2021 - Derek Connolly, MD, PhD - Birmingham, UK - Online CME
Click here to watch this as part of CME accredited course
Video navigation menu
- Benefits of LDL-c lowering can happen very early 0:47
- How are we doing with regard to LDL-c lowering? 3:17
- The ODYSSEY Outcomes and FOURIER trials 3:49
- Provide PCSK9 mAbs at the time of MI 7:51
- Combination therapy in ACS including PCSK9 mAbs 10:19
What is the anticipated reduction in LDL-c with the combination of statin, ezetimibe and PCSK9i?
- A. 45-50%
- B. 60%
- C. 75%
- D. 85%
- E. 95%
This lecture by Derek Connolly was part of an accredited symposium "Redefining intensive LDL-c management in high CV risk patients The case for combination therapy" held during the virtual ESC Congress 2021.
Derek Connolly, MD, PhD is a Consultant Interventional Cardiologist and Honorary Senior Clinical Lecturer at Birmingham City Hospital, Birmingham, UK.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by unrestricted educational grants received from Amgen, Sanofi, Novartis and Daiichi Sankyo.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: